BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Hampel H, Cummings J, Blennow K, Gao P, Jack CR Jr, Vergallo A. Developing the ATX(N) classification for use across the Alzheimer disease continuum. Nat Rev Neurol 2021;17:580-9. [PMID: 34239130 DOI: 10.1038/s41582-021-00520-w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 32] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Kim SE, Kim HJ, Jang H, Weiner MW, DeCarli C, Na DL, Seo SW. Interaction between Alzheimer's Disease and Cerebral Small Vessel Disease: A Review Focused on Neuroimaging Markers. Int J Mol Sci 2022;23:10490. [PMID: 36142419 DOI: 10.3390/ijms231810490] [Reference Citation Analysis]
2 Cheng Y, Zamrini E, Ahmed A, Wu W, Shao Y, Zeng-treitler Q. Medication-Wide Association Study Plus (MWAS+): A Proof of Concept Study on Drug Repurposing. Medical Sciences 2022;10:48. [DOI: 10.3390/medsci10030048] [Reference Citation Analysis]
3 Roe CM. Improving Our Understanding of Driving Changes in Preclinical and Early Symptomatic Alzheimer’s Disease: The Role of Naturalistic Driving Studies. ADR 2022. [DOI: 10.3233/adr-220024] [Reference Citation Analysis]
4 Dulewicz M, Kulczyńska-przybik A, Mroczko P, Kornhuber J, Lewczuk P, Mroczko B. Biomarkers for the Diagnosis of Alzheimer’s Disease in Clinical Practice: The Role of CSF Biomarkers during the Evolution of Diagnostic Criteria. IJMS 2022;23:8598. [DOI: 10.3390/ijms23158598] [Reference Citation Analysis]
5 Strain JF, Brier MR, Tanenbaum A, Gordon BA, McCarthy JE, Dincer A, Marcus DS, Chhatwal JP, Graff-Radford NR, Day GS, la Fougère C, Perrin RJ, Salloway S, Schofield PR, Yakushev I, Ikeuchi T, Vöglein J, Morris JC, Benzinger TLS, Bateman RJ, Ances BM, Snyder AZ, For The Dominantly Inherited Alzheimer Network. Covariance-based vs. Correlation-based Functional Connectivity Dissociates Healthy Aging from Alzheimer Disease. Neuroimage 2022;:119511. [PMID: 35914670 DOI: 10.1016/j.neuroimage.2022.119511] [Reference Citation Analysis]
6 Chen L, Niu X, Wang Y, Lv S, Zhou X, Yang Z, Peng D. Plasma tau proteins for the diagnosis of mild cognitive impairment and Alzheimer's disease: A systematic review and meta-analysis. Front Aging Neurosci 2022;14:942629. [DOI: 10.3389/fnagi.2022.942629] [Reference Citation Analysis]
7 Cummings J, Kinney J. Biomarkers for Alzheimer’s Disease: Context of Use, Qualification, and Roadmap for Clinical Implementation. Medicina 2022;58:952. [DOI: 10.3390/medicina58070952] [Reference Citation Analysis]
8 Park SA, Jang YJ, Kim MK, Lee SM, Moon SY. Promising Blood Biomarkers for Clinical Use in Alzheimer's Disease: A Focused Update. J Clin Neurol 2022;18:401-9. [PMID: 35796265 DOI: 10.3988/jcn.2022.18.4.401] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Therriault J, Zimmer ER, Benedet AL, Pascoal TA, Gauthier S, Rosa-Neto P. Staging of Alzheimer's disease: past, present, and future perspectives. Trends Mol Med 2022:S1471-4914(22)00137-X. [PMID: 35717526 DOI: 10.1016/j.molmed.2022.05.008] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
10 Gao F, Lv X, Dai L, Wang Q, Wang P, Cheng Z, Xie Q, Ni M, Wu Y, Chai X, Wang W, Li H, Yu F, Cao Y, Tang F, Pan B, Wang G, Deng K, Wang S, Tang Q, Shi J, Shen Y. A combination model of AD biomarkers revealed by machine learning precisely predicts Alzheimer's dementia: China Aging and Neurodegenerative Initiative (CANDI) study. Alzheimers Dement 2022. [PMID: 35668045 DOI: 10.1002/alz.12700] [Reference Citation Analysis]
11 Karikari TK, Ashton NJ, Brinkmalm G, Brum WS, Benedet AL, Montoliu-Gaya L, Lantero-Rodriguez J, Pascoal TA, Suárez-Calvet M, Rosa-Neto P, Blennow K, Zetterberg H. Blood phospho-tau in Alzheimer disease: analysis, interpretation, and clinical utility. Nat Rev Neurol 2022. [PMID: 35585226 DOI: 10.1038/s41582-022-00665-2] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 12.0] [Reference Citation Analysis]
12 Gao XL, Wang J, Wang YJ, Bu XL. Combining Multiple Factors to Predict Alzheimer's Disease. Neurosci Bull 2022. [PMID: 35543934 DOI: 10.1007/s12264-022-00868-z] [Reference Citation Analysis]
13 Calderón-garcidueñas L. Common Fatal Neurodegenerative Diseases Revisited: Beyond Age, Comorbidities, and Devastating Terminal Neuropathology There Is Hope With Prevention. Front Neurol 2022;13:901447. [DOI: 10.3389/fneur.2022.901447] [Reference Citation Analysis]
14 Therriault J, Pascoal TA, Lussier FZ, Tissot C, Chamoun M, Bezgin G, Servaes S, Benedet AL, Ashton NJ, Karikari TK, Lantero-rodriguez J, Kunach P, Wang Y, Fernandez-arias J, Massarweh G, Vitali P, Soucy J, Saha-chaudhuri P, Blennow K, Zetterberg H, Gauthier S, Rosa-neto P. Biomarker modeling of Alzheimer’s disease using PET-based Braak staging. Nat Aging. [DOI: 10.1038/s43587-022-00204-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
15 Barisano G, Montagne A, Kisler K, Schneider JA, Wardlaw JM, Zlokovic BV. Blood-brain barrier link to human cognitive impairment and Alzheimer's Disease. Nat Cardiovasc Res 2022;1:108-15. [PMID: 35450117 DOI: 10.1038/s44161-021-00014-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
16 Maschio C, Ni R. Amyloid and Tau Positron Emission Tomography Imaging in Alzheimer’s Disease and Other Tauopathies. Front Aging Neurosci 2022;14:838034. [DOI: 10.3389/fnagi.2022.838034] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
17 Varesi A, Carrara A, Pires VG, Floris V, Pierella E, Savioli G, Prasad S, Esposito C, Ricevuti G, Chirumbolo S, Pascale A. Blood-Based Biomarkers for Alzheimer's Disease Diagnosis and Progression: An Overview. Cells 2022;11:1367. [PMID: 35456047 DOI: 10.3390/cells11081367] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
18 Rossini PM, Miraglia F, Vecchio F. Early dementia diagnosis, MCI-to-dementia risk prediction, and the role of machine learning methods for feature extraction from integrated biomarkers, in particular for EEG signal analysis. Alzheimers Dement 2022. [PMID: 35388959 DOI: 10.1002/alz.12645] [Reference Citation Analysis]
19 Bu XL, Sun PY, Fan DY, Wang J, Sun HL, Cheng Y, Zeng GH, Chen DW, Li HY, Yi X, Shen YY, Miles LA, Maruff P, Gu BJ, Fowler CJ, Masters CL, Wang YJ. Associations of plasma soluble CD22 levels with brain amyloid burden and cognitive decline in Alzheimer's disease. Sci Adv 2022;8:eabm5667. [PMID: 35363517 DOI: 10.1126/sciadv.abm5667] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
20 Smirnov DS, Ashton NJ, Blennow K, Zetterberg H, Simrén J, Lantero-Rodriguez J, Karikari TK, Hiniker A, Rissman RA, Salmon DP, Galasko D. Plasma biomarkers for Alzheimer's Disease in relation to neuropathology and cognitive change. Acta Neuropathol 2022;143:487-503. [PMID: 35195758 DOI: 10.1007/s00401-022-02408-5] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 11.0] [Reference Citation Analysis]
21 Liu P, Wang Y, Sun Y, Peng G. Neuroinflammation as a Potential Therapeutic Target in Alzheimer’s Disease. CIA 2022;Volume 17:665-74. [DOI: 10.2147/cia.s357558] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
22 Pichet Binette A, Palmqvist S, Bali D, Farrar G, Buckley CJ, Wolk DA, Zetterberg H, Blennow K, Janelidze S, Hansson O. Combining plasma phospho-tau and accessible measures to evaluate progression to Alzheimer's dementia in mild cognitive impairment patients. Alzheimers Res Ther 2022;14:46. [PMID: 35351181 DOI: 10.1186/s13195-022-00990-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
23 Calderón-garcidueñas L, Hernández-luna J, Mukherjee PS, Styner M, Chávez-franco DA, Luévano-castro SC, Crespo-cortés CN, Stommel EW, Torres-jardón R. Hemispheric Cortical, Cerebellar and Caudate Atrophy Associated to Cognitive Impairment in Metropolitan Mexico City Young Adults Exposed to Fine Particulate Matter Air Pollution. Toxics 2022;10:156. [DOI: 10.3390/toxics10040156] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
24 Brickman AM, Manly JJ, Honig LS, Sanchez D, Reyes‐dumeyer D, Lantigua RA, Vonsattel JP, Teich AF, Kang MS, Dage JL, Mayeux R. Correlation of plasma and neuroimaging biomarkers in Alzheimer's disease. Ann Clin Transl Neurol. [DOI: 10.1002/acn3.51529] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
25 Huang S, Wang Y, Guo J. Biofluid Biomarkers of Alzheimer’s Disease: Progress, Problems, and Perspectives. Neurosci Bull . [DOI: 10.1007/s12264-022-00836-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
26 Gallucci M, Cenesi L, White C, Antuono P, Quaglio G, Bonanni L. Lights and Shadows of Cerebrospinal Fluid Biomarkers in the Current Alzheimer's Disease Framework. J Alzheimers Dis 2022. [PMID: 35180122 DOI: 10.3233/JAD-215432] [Reference Citation Analysis]
27 Calderón-Garcidueñas L, Chávez-Franco DA, Luévano-Castro SC, Macías-Escobedo E, Hernández-Castillo A, Carlos-Hernández E, Franco-Ortíz A, Castro-Romero SP, Cortés-Flores M, Crespo-Cortés CN, Torres-Jardón R, Stommel EW, Rajkumar RP, Mukherjee PS; Research Universidad del Valle de México UVM Group. Metals, Nanoparticles, Particulate Matter, and Cognitive Decline. Front Neurol 2021;12:794071. [PMID: 35126295 DOI: 10.3389/fneur.2021.794071] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
28 Jansson D, Wang M, Thomas R, Erickson MA, Peskind ER, Li G, Iliff J. Markers of Cerebrovascular Injury, Inflammation, and Plasma Lipids Are Associated with Alzheimer's Disease Cerebrospinal Fluid Biomarkers in Cognitively Normal Persons. J Alzheimers Dis 2022. [PMID: 35124650 DOI: 10.3233/JAD-215400] [Reference Citation Analysis]
29 Ni R, Nitsch RM. Recent Developments in Positron Emission Tomography Tracers for Proteinopathies Imaging in Dementia. Front Aging Neurosci 2021;13:751897. [PMID: 35046791 DOI: 10.3389/fnagi.2021.751897] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
30 Wang J, Fan DY, Li HY, He CY, Shen YY, Zeng GH, Chen DW, Yi X, Ma YH, Yu JT, Wang YJ. Dynamic changes of CSF sPDGFRβ during ageing and AD progression and associations with CSF ATN biomarkers. Mol Neurodegener 2022;17:9. [PMID: 35033164 DOI: 10.1186/s13024-021-00512-w] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
31 Calderón-Garcidueñas L, Stommel EW, Rajkumar RP, Mukherjee PS, Ayala A. Particulate Air Pollution and Risk of Neuropsychiatric Outcomes. What We Breathe, Swallow, and Put on Our Skin Matters. Int J Environ Res Public Health 2021;18:11568. [PMID: 34770082 DOI: 10.3390/ijerph182111568] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
32 Tsantzali I, Boufidou F, Sideri E, Mavromatos A, Papaioannou MG, Foska A, Tollos I, Paraskevas SG, Bonakis A, Voumvourakis KI, Tsivgoulis G, Kapaki E, Paraskevas GP. From Cerebrospinal Fluid Neurochemistry to Clinical Diagnosis of Alzheimer's Disease in the Era of Anti-Amyloid Treatments. Report of Four Patients. Biomedicines 2021;9:1376. [PMID: 34680493 DOI: 10.3390/biomedicines9101376] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
33 Paraskevas GP, Kapaki E. Cerebrospinal Fluid Biomarkers for Alzheimer's Disease in the Era of Disease-Modifying Treatments. Brain Sci 2021;11:1258. [PMID: 34679323 DOI: 10.3390/brainsci11101258] [Cited by in F6Publishing: 1] [Reference Citation Analysis]